Niyati Prasad
YOU?
Author Swipe
View article: ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial
ETD001, a long-acting inhaled ENaC blocker, is well tolerated in a first human, healthy participant trial Open
View article: Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day
Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day Open
In patients with persistent, uncontrolled asthma, increasing the Cic dose from 160 to 640 µg/day provided no clear additional effect. Patients who experience more than one exacerbation per year may benefit from higher doses; however, furth…
View article: Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day
Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day Open
Søren E Pedersen,1 Niyati Prasad,2 Udo-Michael Goehring,3 Henrik Andersson,4 Dirkje S Postma5 1Pediatric Research Unit, Kolding Hospital, University of Southern Denmark, Kolding, Denmark; 2Vertex, Phase IV & Global Strategy, London, UK; 3V…